HMGB1 as A Therapeutic Target in Autoimmune Diseases: The Journey So Far.

Prince Amoah Barnie


Although the adaptive immune system has been a focus of research on joint disease over the past decades, the critical role of innate immunity in the pathogenesis of many autoimmune diseases has been emphasized only in recent years. Treatment of these autoimmune diseases has confronted many challenges. There’s therefore the need to target host pathogenic proteins which influence to a great extent a number of these autoimmune diseases. High-mobility group box-1 (HMGB1), a unique and important pathogenic protein, has been implicated as a pro-inflammatory cytokine in the pathogenesis of various inflammatory and autoimmune diseases. As an important inflammatory factor, HMGB1 is involved in many cardiovascular diseases, autoimmune disease pathogenesis, and CD4 T-cell differentiation and modulation. In this review, we will highlight recent evidence uncovering biological mechanisms of HMGB1 contributing to the pathogenesis of autoimmune immune diseases and as well discuss emerging data on HMGB1 that may inform a novel therapeutic targets in autoimmune diseases.

Key Words: autoimmunity, HMGB1, experimental autoimmune encephalitis, rheumatoid arthritis, experimental autoimmune myocarditis.

Full Text:



  • There are currently no refbacks.